Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139659 · ClinicalTrials.gov registry record · Phase 3
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
NCT00139659 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 288 participants.
The verdict
NCT00139659, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
Study Summary
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Asthma
Interventions
- DRUG Subcutaneous Insulin
- DRUG Inhaled Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2003-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00139659
The ClinicalTrials.gov registry entry for NCT00139659 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Subcutaneous Insulin is the first listed.
NCT00139659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00139659 about?
NCT00139659 is a clinical study titled "A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma". A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Asthma
What is the current status of trial NCT00139659?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2003-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00139659?
The interventions under investigation include: Subcutaneous Insulin (DRUG), Inhaled Insulin (DRUG).
Who is sponsoring clinical trial NCT00139659?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.